Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Urged To Rethink Warning Letters To Avoid ‘Collateral Damage’

Executive Summary

Industry attorneys worry US agency is not considering late responses to adverse inspection reports before issuing warnings, and that letters sometimes go beyond the recommendations laid out in existing FDA guidance

You may also be interested in...



Former FDA Official Calls For 483 Reforms, Notes Caveats

Public scrutiny has made 483 results much more impactful than intended, says Howard Sklamberg, former FDA deputy commissioner for global regulatory operations and policy. He reminds stakeholders that information in them is preliminary.

Moscicki, One Of US FDA's Industry Connections, Moves To PhRMA

One of the faces of FDA's effort to recruit senior leaders from outside its walls has decided to return to industry.

FDA Will Soon Begin Alerting Generics Firms To Facility Compliance Status

US FDA's GDUFA II commitment to alert generics firms within 90 days regarding inspection results will put additional pressure on Form 483 responses, possibly starting later this year.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel